Dajia Weikang: 2025 Annual Performance Forecast
Securities code: 301126 Securities abbreviation: Dajia Weikang Announcement number: 2026-001
Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.
2025 Annual Results Forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
1. Performance forecast for this period
January 1, 2025 to December 31, 2025
Performance forecast: Net profit is expected to be negative
Items This reporting period Operating income in the same period last year RMB 5,500,000,000 ~ RMB 6,000,000,000 RMB 5,233,420,800 attributed to the listed company
-250.00 million yuan ~-300.000 million yuan Shareholders’ net profit of 26.5749 million yuan
Deduct extraordinary losses
-250 million yuan ~-300 million yuan Net profit after earnings of 25.6061 million yuan
2. Communication with the accounting firm
The financial data related to this performance forecast have not been audited by a certified public accountant. The company has pre-communicated with the annual report audit accounting firm on matters related to this performance forecast. There is no disagreement between the company and the annual report audit accounting firm regarding the performance forecast.
3. Explanation of reasons for performance changes
During the reporting period, the chain pharmacy industry as a whole faced changes in the macro market environment and intensified competitive pressure. Combined with multiple factors such as industry policy adjustments and changes in consumption habits, the performance of the company's chain pharmacy sector experienced a periodic decline;
During the reporting period, the subsidiaries acquired in the previous period were affected by the above-mentioned industry environment, own operations and business integration and other factors, and the actual operating performance did not meet the expectations at the time of acquisition. Based on the principle of prudent financial evaluation, the company conducted an impairment test on the goodwill formed by the acquisition of relevant subsidiaries, and made corresponding goodwill impairment provisions. This resulted in a large amount of asset impairment losses in the current period, which had a significant impact on the current profits.
4. Other related instructions
This performance forecast is a preliminary estimate made by the company's financial department and has not been audited by an accounting firm that audits the annual report. Specific financial data are subject to the 2025 annual report disclosed by the company. Investors are advised to make prudent decisions and pay attention to investment risks.
5. Documents for reference
- Explanation of the board of directors’ performance forecast for 2025.
Announcement is hereby made.
Board of Directors of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.
January 26, 2026